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Resistance to existing classes of antibiotics drives
the need for discovery of novel compounds with
unique mechanisms of action. Nargenicin A1, a natu-
ral product with limited antibacterial spectrum, was
rediscovered in a whole-cell antisense assay. Macro-
molecular labeling in both Staphylococcus aureus
and an Escherichia coli tolC efflux mutant revealed
selective inhibition of DNA replication not due to gyr-
ase or topoisomerase IV inhibition. S. aureus narge-
nicin-resistant mutants were selected at a frequency
of 1 3 109, and whole-genome resequencing
found a single base-pair change in the dnaE gene,
a homolog of the E. coli holoenzyme a subunit. A
DnaE single-enzyme assay was exquisitely sensitive
to inhibition by nargenicin, and other in vitro charac-
terization studies corroborated DnaE as the target.
Medicinal chemistry efforts may expand the spec-
trum of this novel mechanism antibiotic.
INTRODUCTION
There is an urgent need for new antibiotics due to the continuing
emergence of resistance to those in common use today. Anti-
microbial drug resistance is an epidemic, with nearly 20% of
healthcare-associated infections considered to be multidrug-
resistant, including methicillin-resistant Staphylococcus aureus
(MRSA), Escherichia coli, and Pseudomonas aeruginosa (Sievert
et al., 2013). Indeed, there are pathogens encountered today
with resistance to all marketed antibiotics. In 2010 the Infectious
Diseases Society of America called for the development of ten
new antibacterial agents from new targets or existing antibacte-
rial classes by the year 2020 (10 x ’20) to combat the issue of
antibacterial resistance which the World Health Organization
has identified as one of the three greatest threats to human1362 Chemistry & Biology 22, 1362–1373, October 22, 2015 ª2015 Ehealth (Infectious Diseases Society of America, 2010). The
recognition of bacterial antibiotic resistance has now achieved
national importance with the publication of threat levels for
various organisms by the Centers of Disease Control and Pre-
vention (United States Department of Health and Human Ser-
vices and Centers for Disease Control and Prevention, 2013),
and the recent National Action Plan For Combating Antibiotic-
Resistant Bacteria issued by the Obama administration.
Recent reviews have highlighted current prospects for new
antibacterials (Pucci and Bush, 2013; Page and Bush, 2014),
although many large pharmaceutical companies have exited
the field (Projan and Shlaes, 2004). The reasons for the dearth
of new antimicrobials are many (Silver, 2013). The traditional
source for antimicrobials is natural products; however, the re-
sources required for producing, dereplicating, and isolating nat-
ural products are expensive and require unique skill sets, and
thus this is a dwindling resource at major pharmaceutical com-
panies. New antimicrobials must be ‘‘non-inferior’’ and as safe
or more safe than the best antimicrobials developed over the
last 70 years. The factors affecting small-molecule permeability
are unknown and, while enzyme assays may yield interesting
and specific inhibitors, converting these to compounds with
whole-cell activity has proved to be nearly impossible (Payne
et al., 2007). Regulatory and clinical complexities require large
costly trials, although there has been recent acceptance by
both domestic and international regulatory agencies of trials
testing antibacterials versus specific organisms rather than
anatomical sites. In short, the unmet medical need is enormous
but the commercial opportunities have been challenging.
Antisense technology has proved successful for the disco-
very of antibacterials with novel mechanisms of action (Singh
et al., 2011). Developed at Elitra Pharmaceuticals in a liquid
culture format (Forsyth et al., 2002), the technology utilizes a
xylose-inducible plasmid to express specific antisense RNA in
S. aureus, thereby reducing expression of the cognate target
and sensitizing the strain to compounds that act through that
gene product. The antisense-induced strain sensitivity (AISS)
method, a panel of 245 isogenic isolates, was successful inlsevier Ltd All rights reserved
identifying a novel gyrase inhibitor, kibdelomycin (Phillips et al.,
2011). Antisense technology was adapted to agar diffusion
methodology and employed in natural products drug discovery
(Young et al., 2006). Different pathway genes have been ex-
ploited with this approach, leading to the discovery of novel
inhibitors, notably the fatty acid biosynthesis inhibitors platenci-
mycin and platencin (Wang et al., 2006, 2007).
One underexploited opportunity for antibacterial develop-
ment is the replication of chromosomal DNA. Replication is
one of the most fundamental processes carried out by bacteria;
however, therapeutically useful inhibitors only have been devel-
oped for processes upstream (nucleotide precursor biosyn-
thesis) (Hawser et al., 2006) and downstream (type II topoiso-
merases) (Wolfson and Hooper, 1989) of DNA replication. The
mechanisms underlying bacterial DNA replication are becoming
increasingly well understood, particularly in E. coli and Bacillus
subtilis, where complete replisome complexes have been re-
constituted from individually purified components and are fully
functional in vitro. The replisome is a macromolecular machine
encompassing at least 13 protein subunits, most of which are
essential, suggesting that their inhibition would be detrimental
to cell survival (O’Donnell and Studwell, 1990; Sanders et al.,
2010). While there are elements in common between bacterial
and eukaryotic replication, there are numerous processes that
are absent or distinct between the two, allowing for selective in-
hibition of bacterial replication (Robinson et al., 2012). Recent
discovery and development efforts for both clinically validated
(gyrase; GSK299423 and kibdelomycin) and novel targets
(DNA ligase and DNA helicase) have found novel chemical mat-
ter but have had little clinical success to date (Brotz-Oesterhelt
et al., 2003; Aiello et al., 2009; Bax et al., 2010; Phillips et al.,
2011). Other DNA replication inhibitors have been described,
such as the Gram-positive DNA Pol IIIc inhibitors (Zhi et al.,
2003).
Combining the established antisense agar diffusion approach
to the underexploited DNA pathway led us to screen antisense-
expressing plasmids to multiple genes involved in DNA replica-
tion including gyrB and parE. Nargenicin A1 (hereafter referred
to as nargenicin), a known natural product with an unknown
mechanism of action, was isolated from this assay. The target
of nargenicin was identified through resistant mutant selection
followed by comparative genome sequencing (NimbleGen
CGS) and confirmed to be DnaE.
RESULTS
Discovery and Antibacterial Spectrum
As part of the antibacterial screening effort described previously
(FabF) utilizing target-based whole-cell screens with antisense
technology (Young et al., 2006), natural product extracts were
tested in strains expressing antisense for either GyrB or ParC.
Compared with the parent containing the empty vector as
control, a fermentation broth extract of a wild-type isolate
of Nocardia devorans gave zone of inhibition differentials of
3–6mmversus GyrB, and 2–3mm versus ParC (data not shown).
Isolation of the active component through amberchrome and
high-performance liquid chromatography (HPLC) revealed a
known compound of molecular weight 515 and molecular for-
mula C28H37NO8, identified as nargenicin A1, by a complete nu-Chemistry & Biology 22, 1362–1clear magnetic resonance analysis (Figure 1A). The first nargeni-
cin publications describe its potent anti-Staphylococcus activity
that is efficacious in both intraperitoneal and oral S. aureus mu-
rine models of infection, but with a limited antibacterial spectrum
(Celmer et al., 1980; Magerlein and Mizsak, 1982; Magerlein and
Reid, 1982). Testing confirmed the largely anti-Staphylococcus
activity (Figure 1C); however, the potent inhibition of a sensitized
E. coli (lpxC, tolC mutant) hinted at the potential for a broader
range of activity.
To explore further the basis of this Gram-negative activity, nar-
genicin was tested in microbroth minimum inhibitory concentra-
tions (MICs) utilizing an isogenic E. coli strain set with mutations
in permeability (lpxC), efflux (tolC), or both (Kodali et al., 2005),
and also in P. aeruginosa, utilizing an isogenic set of efflux
pump knockouts (Robertson et al., 2007; Singh et al., 2015;
and this study). Results showed that the compound was sub-
ject to efflux in E. coli through the AcrAB/TolC efflux pump
(Figure 1C). Nargenicin was also shown to be effluxed in
P. aeruginosa, but a single-efflux deleted strain for the MexAB/
OprM pump was not available. By subtractive reasoning from
single-, double-, and triple-efflux pump knockouts the pumps
MexAB/OprM and MexJKL were implicated as possibilities
(Table S1). Haemophilus influenzae was similarly sensitized to
nargenicin analog B1 (Figure 1B) when acrB and tolC were
knocked out (Table S2); however, efflux was not found to cause
the lack of activity of the nargenicin analog B1 in Streptococcus
pneumoniae when it was examined in a panel of S. pneumoniae
efflux knockouts (Table S2).
Whole-Cell Characterization of Nargenicin Points to
Inhibition of DNA Replication
The effects of nargenicin on macromolecular synthesis path-
ways were determined in S. aureus with radiolabeled precursors
for DNA, RNA, protein, phospholipid, and cell wall across a range
of concentrations. This revealed that nargenicin was an exqui-
sitely selective inhibitor of DNA synthesis, a property not previ-
ously reported for this compound (Figure 2A). Due to the antibac-
terial activity seen in the E. coli tolC mutant, macromolecular
labeling was also investigated in this Gram-negative organism.
Interestingly, nargenicin also displayed a selective DNA inhibi-
tion response in E. coli (Figure 2B), indicating that the antibacte-
rial activity of nargenicin was likely due to a target that existed in
both Gram-positive and Gram-negative organisms.
Although nargenicin was observed to cause modest differen-
tials in the GyrB and ParC whole-cell screens, gel-based assays
for gyrase supercoiling and topoisomerase IV decatenation ac-
tivity (Phillips et al., 2011) showed that it was not an inhibitor of
either of these functions (data not shown), despite the DNA syn-
thesis inhibition in macromolecular pathway assay. Therefore,
nargenicin was compared with known DNA synthesis inhibitors
of various mechanisms of action in standard assays for charac-
terization of DNA synthesis inhibitors: the SOS chromotest assay
(Wang et al., 2003; Gonzalez del Val et al., 2003), the relative sus-
ceptibility of DNA repair-proficient and -deficient UvrA-positive
versus UvrA-negative isogenic strains (Gonzalez del Val et al.,
2003), and DNA binding interference to antibacterial susceptibil-
ity. Results summarized in Figure 2C showed that nargenicin was
an inducer of the SOS response but was neither a UV mimetic
nor a DNA intercalator.373, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1363
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Figure 1. Antibacterial Activity of Nargenicin
(A) Structures of nargenicin A1 and (B) nargenicin B1.
(C) Minimum inhibitory activity (MIC) of nargenicin in a panel of wild-type
bacteria, pathogenic isolates, and defined strains with mutations in perme-
ability and efflux (Phillips et al., 2011; Kodali et al., 2005; Robertson et al., 2007;
Singh et al., 2015; Huber et al., 2009; Gefter et al., 1971).
1364 Chemistry & Biology 22, 1362–1373, October 22, 2015 ª2015 ENargenicin was tested in kill curves at 43, 83, and 163 MIC
and was shown to give a 4-log decrease in cell viability within
4 hr in the MRSA strain COL (Figure 3). At four times the MIC
the data are at the limit of detection (one colony) after 5 hr,
whereas for 83 MIC the data dropped below the limit of detec-
tion at 6 hr. At 163 MIC, slight regrowth was observed after
5 hr. Representative colonies were tested, and all were suscep-
tible to nargenicin. This result compares favorably with time-kill
studies of fluoroquinolone antibiotics against MRSA (Entenza
et al., 1997). Treatment of E. coli tolC cells with MIC concen-
tration of nargenicin resulted in filamentation similar to that
observed for ciprofloxacin (Figure S2A). There are many exam-
ples of a filamentation phenotype in response to non-permissive
temperature shifts in temperature-sensitive DNA replication mu-
tants, including the replicative polymerase DnaE, the gyrase A
subunit mutant NalA, initiation proteins DnaA and DnaC, and
the elongation protein DnaB (Gefter et al., 1971; Kreuzer and
Cozzarelli, 1979; Jaffe et al., 1986; Hishida et al., 2004). The
morphology observed for nargenicin-treated cells compared
favorably with that of the dnaE486(ts)mutant at the non-permis-
sive temperature (Figure S2B) (Vandewiele et al., 2002). This
result supported the finding that nargenicin inhibited DNA specif-
ically in macromolecular labeling and that the inhibitor was
potentially phenocopying an essential step in DNA replication,
but could not definitively point to a specific target.
Taken together, the DNA synthesis inhibition in macromolec-
ular labeling, SOS induction, lack of DNA intercalation, or UvrA
repair-mediated damage, and induction of filamentation repre-
sented desirable properties worthy of further characterization
of the mechanism of action of the compound.
Nargenicin Is a Potent and Selective Inhibitor of the
Bacterial DNA Polymerase DnaE
In an attempt to identify the target of nargenicin, we profiled it in
the 245-strain antisense panel. The AISS profile of nargenicin
suggested a DNA replication target pathway effect with several
depletions of genes involved in DNA biosynthesis or replication,
including holB, dnaX, and polC (Figure S1). The profile was not
like that of the fluoroquinolones or coumarin antibiotics (Phillips
et al., 2011), suggesting that nargenicin had a different mecha-
nism of action.
To determine the target of nargenicin, we selected resistant
isolates of S. aureus COL on 2 mg/ml (4–83MIC; MIC varied be-
tween 0.25 and 0.5 mg/ml) at a frequency of 1 3 109. No mu-
tants were obtained above 2 mg/ml. Two isolates were obtained
at 24 hr of incubation and an additional two at 48 hr of incubation.
These isolates had a 16- to 32-fold increase in the nargenicin
MIC, from 0.25–0.5 mg/ml to 8 mg/ml. The predominant genes
observed to be depleted in the AISS profile upon challenge
with nargenicin were amplified by PCR and sequenced; no mu-
tations were found, so a different approach was taken. The ge-
netic change responsible for nargenicin resistancewas identifiedlsevier Ltd All rights reserved
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Figure 2. Characterization of Nargenicin as an Inhibitor of DNA
Synthesis
(A and B) Selective inhibition of DNA synthesis by nargenicin in S. aureus
(A) and E. coli (B) across the indicated drug concentrations was determined
by measuring incorporation of radiolabeled precursors of either DNA (14C-
thymidine), RNA (3H-uridine), phospholipid (2-3H-glycerol), protein (3H-
leucine), or cell wall (14C-glycine) synthesis.
(C) Nargenicin turned on the SOS response, eliciting a blue ring due to in-
duction of the sulA promoter driving b-galactosidase. Nargenicin had equal
activity against a UvrA mutant, indicating inhibition of DNA replication was not
due to the addition of bulky adducts. Nargenicin had equal activity in the
Chemistry & Biology 22, 1362–1by comparing the genomes of a parent/resistant pair using an
array-based DNA hybridization and comparison service (CGS).
Two mutants were analyzed, one from 24 hr and one from
48 hr. One high-probability, non-synonymous SNP was deter-
mined by CGS nucleotide change for the 24-hrmutant. Three hy-
bridization probes overlapping the same SNP failed for the
mutant, with one difference in each at chromosome location
1,789,500. This nucleotide change was confirmed by PCR
amplification and sequencing of 600 bp surrounding the putative
mutation, revealing a C/T transition at nucleotide 2,294 of
dnaE, resulting in a serine to leucine substitution at amino acid
765 of the protein. S. aureus DnaE is the homolog of the E. coli
DNA polymerase III a subunit, an essential protein required for
DNA replication. The 48-hr mutant gave a non-synonymous
SNP in pbpA which was not confirmed by Sanger sequencing.
In addition, dnaE was sequenced and no SNPs were identified;
thus, the mechanism of increased nargenicin MIC in the 48-hr
mutant has not yet been determined.
To explore the significance of this mutation identified in the
DnaE of S. aureus, we constructed an E. coli/S. aureus shuttle
vector, pTET15, harboring either the wild-type or nargenicin-
resistant DnaE allele S765L, and introduced it into S. aureus
COL, rendering it a diploid (Figure 4C). With wild-type COL
as the host, the plasmid-borne nargenicin-resistant DnaE
allele raised the MIC of nargenicin 16-fold (from 0.25 mg/ml to
4 mg/ml), similar to what was seen in the initial resistance selec-
tion. COL hosts with a plasmid bearing the wild-type allele or a
vector-alone control had no change in their nargenicin MIC.
Conversely, when the nargenicin-resistant mutant was used as
the host for a vector-alone control or plasmids bearing either
the wild-type or resistant allele, no change in their nargenicin
MIC was observed. Taken together, these results indicated
that themutation in DnaEwas necessary and sufficient for narge-
nicin resistance, and that the resistant genotype was dominant.
To establish that nargenicin directly inhibits DNA Pol IIIE, we
adapted a single-enzyme assay from a previously published
method for Pol IIIC (Butler and Wright, 2008). Nargenicin was
able to inhibit the polymerization catalyzed by Pol IIIE from
both S. aureus and E. coli using nucleotides and an ‘‘activated’’
DNA template substrate with a half-maximal inhibitory concen-
tration (IC50) of 0.0003 mg/ml and 1 mg/ml, respectively (Figures
4A and 4B). Ciprofloxacin and novobiocin, inhibitors of GyrA
and GyrB, respectively, as well as the known Gram-positive
PolIIIC DNA replication inhibitor 6-(phenylhydrazino)uracil,
were all inactive in the DnaE assay (Figures 4A and 4B). The
assay was not sensitive to DNA template active agents (strep-
tonigrin, griseolutein, mitomycin C, echinomycin, and actino-
mycin D), or compounds with other mechanisms of action
(ampicillin, streptomycin, and fosfomycin) (data not shown).
To ensure the specificity of nargenicin, we tested it against hu-
man DNA polymerases a, b, and g; no inhibition was seen (data
not shown).
Several analogs of nargenicin have been published previously
(Magerlein and Reid, 1982; Magerlein and Mizsak, 1982), andpresence and absence of DNA, indicating lack of DNA binding or intercalation.
Positive controls ciprofloxacin, mitomycin C, griseolutein, and actinomycin D
behaved as expected.
373, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1365
Figure 3. Further Characterization of the Biological Activity of
Nargenicin
Upon addition of nargenicin to logarithmically growing cells of Col MRSA,
immediate killing was observed. A 3-log10 reduction in viable colony-forming




Figure 4. Biochemical and Genetic Evidence that DnaE is the Target
of Nargenicin
(A and B) S. aureus (A) or E. coli (B) DnaE single-enzyme polymerization assays
were incubated with activated calf thymus DNA and four dNTPs, including 3H-
dTTP, in the presence of several inhibitors of DNA synthesis. Compounds
such as ciprofloxacin and novobiocin, known to target gyrase, show no
effect against DnaE. Dose-response curves were plotted using GraphPad
Prism software; where samples were tested in triplicate, error bars represent
the SEM.
(C) Episomal expression of mutant DnaE conferred resistance to nargenicin
when S. aureus COL was grown for 20 hr in cation-adjusted Mueller-Hinton
broth supplemented with chloramphenicol (25 mg/ml) and anhydrotetracycline
inducer (20 ng/ml).a subset of these were synthesized and characterized for whole-
cell and single-enzyme activity (Table 1). Compared with com-
pound 1, the incorporation of the pyrrole-20-carbonyl group at
the C-9 position in nargenicin (compound 2) was critical for its
S. aureus activity in both enzymatic and cellular assays (150-
fold and 256-fold, respectively, versus compound 1). The same
trend was observed for its E. coli activity, although the difference
in cellular activity was only 8-fold.
The N-H group of the pyrrole was also critical as its N-methyl
analog compound 6 lost its activity against both S. aureus and
E. coli. Saturation of the 20-pyrrole ring (compound 5) also led
to a nearly 100-fold drop in its activity against both isolates.
The replacement of 20-pyrrole with 30-thiophene resulted in
compound 4, with slightly lower potency against both organisms
compared with nargenicin. The hydroxyl group at C-18 (com-
pound 3 versus compound 2) improved the activity by 10-fold
against both isolates. An unexplained disconnect was only
observed for compound 5 between E. coli whole-cell and
enzyme activity.
Analysis of Ligand Binding by AS/MS
Affinity selection/mass spectrometry (AS/MS) was applied to
confirm direct binding of nargenicin to DnaE. For a standard
AS experiment applying an integrated size-exclusion chroma-
tography-liquid chromatography-mass spectrometry (SEC-LC-
MS) platform (Adam et al., 2008), anywhere from one to a
mixture of several hundred compounds is pre-incubated with
the protein target, and a portion of this mixture is injected into
an integrated two-step LC-MS system where a fast SEC column
rapidly separates the protein and protein-bound ligands from
unbound compounds. The excluded protein peak containing
the bound small molecules is then trapped and diverted to a
reverse-phase column (RPC) where proteins are denatured
and ligands detected by LC-MS. After pre-incubation of narge-
nicin with S. aureus DnaE in the presence or absence of 0.5 mg/
ml activated DNA (Figure 5A), the samples were analyzed by1366 Chemistry & Biology 22, 1362–1373, October 22, 2015 ª2015 EAS/MS and the integrated MS response at m/z = 516.2, which
correlates to M + H for nargenicin, was calculated. Minimal
binding was detected for nargenicin binding to S. aureus
DnaE alone; however, a >200-fold increase in integrated MS
response was detected for the enzyme incubated with activated
DNA. In contrast, nargenicin bound to E. coli DnaE indepen-
dently of the presence or absence of activated DNA (Figure 5B).
Daunorubicin, a known DNA intercalator, was recovered as
bound to activated DNA with or without DnaE but not to either
species of DnaE alone.
To confirm further that binding of nargenicin to DnaE is selec-
tive, we incubated 10 mM nargenicin with a panel of proteins andlsevier Ltd All rights reserved
Table 1. Structure-Activity Relationship of Nargenicin Analogs
No. S. aureus IC50
a E. coli IC50
a S. aureus MICa E. coli tolC MICaR1 R2
1 H OH 0.045 100 64 2
2b OH 0.0003 1 0.25 0.25
3 H <0.006 10 2 2
4 OH <0.006 2 1 1
5 OH 0.028 >100 128 4
6 OH 5.2 100 >128 64
amg/ml.
bNargenicin.measured its binding using AS/MS (Figure 5C). Nargenicin
bound to S. aureus DnaE and E. coli DnaE, but no binding was
detected with b-lactoglobulin or P-38 mitogen-activated protein
kinase (P-38 MAPK) and minimal binding was detected with
human serum albumin (HSA). Neither warfarin nor SB203580, a
P38 inhibitor (controls for binding to HSA and P-38 MAPK,
respectively), demonstrated appreciable binding to DnaE, indi-
cating that the protein is not promiscuous in the AS/MS
format and that activated DNA does not cause non-specific
ligand binding. Together these data provide evidence that narge-
nicin binds to E. coli DnaE independent of activated DNA, and
binds to S aureus DnaE with affinity enhanced in the presence
of activated DNA.Chemistry & Biology 22, 1362–1Lack of Pre-existing Resistance in Clinical Panels
of S. aureus and CoNS
Nargenicin was tested in large panels of clinical isolates of
S. aureus and coagulase-negative Staphylococcus (CoNS)
compared with standard antibiotics (Tables S3 and S4). Against
98 S. aureus isolates, nargenicin gave an MIC50/MIC90 of 0.125/
0.5 mg/ml, the lowest of any antibiotic tested. The MIC90 of all
tested clinically available antibiotics was above the susceptibility
breakpoint set by the Clinical and Laboratory Standards Institute
(2015), and the MIC50 was above the breakpoint for oxacillin,
erythromycin, and levofloxacin (Table S3). Among CoNS, with
the exception of Staphylococcus saprophyticus the MIC90 for
nargenicin was generally low (1–4 mg/ml) (Table S4). Linezolid373, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1367
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Figure 5. Binding of Nargenicin to DnaE in the Absence and Pres-
ence of DNA
(A) The amount of nargenicin bound to 3.9 mM S. aureus DnaE is increased in
the presence of 0.5 mg/ml activated DNA. Binding to DnaE was selective for
nargenicin, and nargenicin did not bind to activated DNA alone like the DNA
intercalator daunorubicin. Data are reported as the integrated mass spectral
response for the extracted ion chromatogram (XIC) of the ligand.
(B) However, for E. coli DnaE, binding of nargenicin to the protein was not
increased by the presence of activated DNA.
Figure 6. Nargenicin Is Active in Systemic In Vivo Model of MSSA by
Both Oral and Subcutaneous Routes of Administration
Balb/c mice (five per group) were challenged intraperitoneally with S. aureus
MB 2865 in 5% hog gastric mucin at 2.2 3 103 cfu/mouse. Mice were treated
orally or subcutaneously with compounds receiving two total doses (0.5 ml,
twice daily for 1 day). Kidneys were collected aseptically at 24 hr after
challenge.
1368 Chemistry & Biology 22, 1362–1373, October 22, 2015 ª2015 Eand vancomycin were more active than nargenicin for these
groups of organisms by 1- to 4-fold and 1- to 2-fold, respectively.
With the exception of Staphylococcus schlieferi, the MIC90 for
oxacillin was above the breakpoint for all species of CoNS. In
summary, there was no cross-resistance observed between nar-
genicin and any antibiotic tested, and no apparent naturally
occurring resistance; however, among S. saprophyticus the
MIC90 was 16 mg/ml, higher than for any other species.
Nargenicin Shows In Vivo Efficacy in Murine Models
Nargenicin was tested in a disseminated model of infection us-
ing the S. aureus MSSA (methicillin-sensitive S. aureus) strain
Smith (MB2865) (Figure 6). When dosed orally at 50 mg/kg/
dose, a 5-log reduction was observed. When the dose was
titrated to 25 mg/kg/dose, a 3-log reduction in kidney organ
burden was seen. Although the relevant pharmacokinetic/phar-
macodynamic parameter is not known for this compound class
and mechanism of action, the blood concentration remained
above the MIC for 1 hr after oral dosing at 25 mg/kg. Nargenicin
was also active in an MRSA Col thigh 7-day model. When dosed
orally at 25 or 12.5 mg/kg the log reduction from sham was 2.27
and 1.28, respectively. When dosed subcutaneously, the log re-
ductions at 25 and 12.5 mg/kg were 4.63 and 3.41, respectively.
While efficacy in murine models was reported previously, mini-
mal data were shown (Magerlein and Reid, 1982; Snyder and Ri-
nehart, 1984). This study expands on that work and demon-
strates the bactericidal nature of nargenicin not just in vitro
but also in vivo.(C) The increase in binding in the presence of activated DNA is selective for the
S. aureus nargenicin-DnaE interaction. The binding of warfarin and SB-203580
to human serum albumin and P-38aMAPK, respectively, was the same in the
presence and absence of 0.5 mg/ml activated DNA. Binding of nargenicin was
selective for DnaE with only minimal non-specific binding detected to HSA.
Data are reported as the normalized integrated mass spectral response for the
XIC of the ligand where the largest signal for each ligand is normalized to 1.
lsevier Ltd All rights reserved
DISCUSSION
The antisense platform has been fruitful in identifying new natural
product inhibitors of various mechanisms of action (Wang et al.,
2006, 2007; Phillips et al., 2011). Nargenicin was rediscovered in
an antisense assay targeting gyrase and topoisomerase, and
although gyrBwas identified in the AISS profiling (Figure S1), nar-
genicin was not active in in vitro enzyme assays for these targets.
This was not completely unexpected, since we have observed
that antisense-reduced expression of one protein in a pathway
often results in a pleiotropic effect that sensitizes other genes
in the pathway; for example, in the current study it was observed
that the most highly depleted genes upon treatment with narge-
nicin were holB, dnaX, and polC, while for the natural product
gyrase inhibitor kibdelomycin, rplT, hu, and polC were also
strongly affected in addition to the gyrase/topoisomerase genes
gyrB, parC, and parE (Phillips et al., 2011).
Induction of filamentation was observed, a phenotype consis-
tent with DNA replication inhibitors such as the fluoroquinolones.
Filamentation can be caused by other mechanisms such as inhi-
bition of cell division (Ricard and Hirota, 1973; Wang et al., 2003)
or induction of SOS through DNA damage; however, the specific
inhibition of [3H]thymidine in macromolecular labeling pointed to
DNA synthesis as the pathway of antibacterial activity, as did the
AISS profiling. Lack of reversal in the UvrA+/ isogenic strain set
indicated lack of DNA damage through a UV mimetic effect. The
lack of Gram-negative spectrum was shown to be due to efflux
when the target responsible for antibacterial activity as well as
DNA synthesis inhibition was confirmed to be present in Gram-
negative E. coli in a tolC mutant.
Nargenicin-resistant mutants that were selected during com-
pound characterization were examined by targeted sequencing
of some of the genes involved in DNA replication (dnaX, holB,
and so forth), but no mutations were found. Using an array-
based complete-genome comparison (CGS, NimbleGen) tech-
nology, a mutation in S. aureus DnaE, S765L, was revealed
and later confirmed with PCR and Sanger sequencing. Genetic
evidence strongly corroborates DnaE as the target of nargenicin,
since cloning of the wild-type and mutant dnaE genes and
expression on a plasmid in both wild-type and mutant host
strains demonstrated that the mutation was both necessary
and sufficient for the resistance phenotype. Similarly, biochem-
ical evidence also substantiates the target, since DnaE was
shown to be exquisitely sensitive to nargenicin in a single-
enzyme assay utilizing DNase I activated DNA as a substrate.
This process introduces single-strand gaps providing 30-OH for
priming and association of replication proteins. Differences
were observed in the binding of nargenicin to S. aureus or
E. coli DnaE, depending on the presence of activated DNA,
which may be reflective of the roles played by DnaE in Gram-
positive versus Gram-negative organisms. Although nargenicin
was identified in a gyrase antisense assay, there is no cross-in-
hibition of nargenicin for gyrase or topoisomerase IV assays.
Notably, there was also no cross-inhibitory activity of ciproflox-
acin or coumermycin for S. aureus DnaE, and limited activity of
ciprofloxacin (1,000-fold MIC) or coumermycin seen in the
E. coli DnaE single-enzyme assay.
Bacterial DNA replication is carried out by a complex set of
proteins referred to as the replisome. The main replicative poly-Chemistry & Biology 22, 1362–1merase, the Pol III a subunit, comes in two major forms, DnaE
and PolC. While DnaE1 is the lone polymerase in the majority
of bacterial genomes (such as E. coli), in low-GC Gram-positive
bacteria two DNA Pol IIIs exist, termed PolC and DnaE3 (Zhao
et al., 2006). They are homologous, but the functional domains
of PolC are rearranged, and it contains an endogenous proof-
reading activity. DnaE3 is more closely related to the replicative
E. coli Pol III a subunit; however, the elongation rate of DnaE is
too slow (25 nt/s) to keep up with the replication fork (Sanders
et al., 2010). PolC, on the other hand, supports a physiologically
relevant elongation rate (500 nt/s) (Sanders et al., 2010). In
B. subtilis, PolC discriminates against RNA primers while DnaE
uses RNAprimers efficiently (Sanders et al., 2010). This suggests
that in Gram-positive bacteria DnaE initially extends the RNA
primers necessary for lagging strand replication and then hands
them off to the processive replicase PolC. Model systems using
RNA-primed single-stranded DNA show inefficient use by PolC,
with an enhanced rate of synthesis stimulated by low concentra-
tions of DnaE greater than that achieved by DnaE alone (Sanders
et al., 2010). The resistance mutation was dominant when both
wild-type and mutant were expressed in the same cell, whether
on the chromosome or on a plasmid. Dominance may indicate
that when wild-type DnaE is inhibited by nargenicin and replica-
tion stalls and dissociates, mutant protein can associate to
extend RNA primers and subsequently permit processive repli-
cation by PolC.
To understand the difference in binding of nargenicin to DnaE
from S. aureus and E. coli in the presence of DNA, we modeled
the S. aureus amino acid sequence onto the Thermus aquaticus
DNA polymerase III/DNA complex X-ray structure (Wing et al.,
2008) using the homology modeling approach. This structure
was chosen rather than the E. coli (Lamers et al., 2006) because
theE. coli structural work utilized a truncated protein, missing the
CTD domain, whereas the T. aquaticus structure was solved in
the presence and absence of DNA (Bailey et al., 2006; Wing
et al., 2008; Liu et al., 2013). Based on the structural model of
S. aureus DnaE, the nargenicin mutation site S765 is located in
the b-binding domain (b-BD) (Bailey et al., 2006), near the DNA
binding site (Figure S3A). The b-BD has shown large conforma-
tional changes upon binding of DNA or the t subunit of the clamp
loader (Wing et al., 2008; Liu et al., 2013), indicating high mobility
of this domain and possible formation of an allosteric binding site
for nargenicin in the S765 region. Sequence alignment of
S. aureus and E. coli DnaE (Figure S3B) reveals several residue
differences in the S765 region between S. aureus and E. coli
DnaE, potentially influencing the binding of nargenicin, assuming
nargenicin binds near the S765 mutation site, which might
explain the binding differences seen between S. aureus and
E. coli. An X-ray structure of DnaE/nargenicin could provide
more insight into the binding interactions of nargenicin with
DnaE from various species in the presence and absence of DNA.
This natural product represents the first report of a DnaE inhib-
itor that results in disruption of DNA synthesis sufficient enough
to inhibit growth. Synthetic chemical PolC inhibitors with a nar-
row Gram-positive spectrum were modified to include in vitro
biochemical inhibition of DnaE; however, in PolC mutants there
was no observed antibacterial activity and, therefore, the DnaE
inhibition was not biologically significant (Barnes et al., 2012).
Although nargenicin inhibited DnaE enzymatic activity in a373, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1369
biochemical assay, there remains a formal possibility that PolC
could be inhibited as well, since this was not tested. There is
no PolC in Gram-negative bacteria, so at least in E. coli DnaE
is presumed to be the sole target and, since the mutation to
resistance in S. aureuswas in DnaE, it is presumed to be the ma-
jor target. The lack of S. pneumoniae activity is not as easily ex-
plained, since Gram-positive organisms do not have RND-type
tripartite efflux pumps and there was no evidence that a lack of
Gram-positive broad-spectrum activity was due to efflux in
S. pneumoniae. There was also no activity of nargenicin against
B. subtilis. Therefore, the limitation of Gram-positive activity may
be due to differences in target. Nargenicin will be a useful tool in
furthering understanding of protein requirements and roles in
DNA replication in Gram-positives. Nargenicin, or one of its ana-
logs, may also be useful as a Staphylococcus-only therapeutic in
light of the unique mechanism of action, oral and intravenous
bioavailability, low potential for resistance, and lack of cross-
resistance with existing agents. The narrow spectrum would
require diagnostics.
Natural products remain a good source for new antibacterial
agents (Ling et al., 2015). Sifting through the low-hanging fruit
of noxious compounds as well as natural products discovered
over the last 70 years (dereplication) remained a critical issue
in natural products drug discovery, although pathway screening
and the use of novel sources can be helpful (Singh et al., 2011;
Silver, 2013; Ling et al., 2015). Recently, Lewis and colleagues
(Ling et al., 2015) reported success with identifying a novel anti-
bacterial from a non-culturable organism, a technique involving
novel sources which could reduce the need for dereplication
(Ling et al., 2015). Optimization of novel compounds is often
more straightforward once the target has been elucidated and
appropriate assays can be developed. Selection of resistant mu-
tants followed by whole-genome sequencing has proved to be a
powerful approach in identifying the target of novel antimicro-
bials (Friedman et al., 2006; Mann et al., 2013). This technique
could be particularly useful for known natural products with un-
known mechanisms of action, whereby it is worth a second look
to determine targets and validate them using chemical biology,
exemplified in this report as well as recent literature (Srivastava
et al., 2011).With newer understanding of the biology of bacterial
permeability and efflux as well as the pharmacophores that
contribute to efflux substrate potential, medicinal chemistry
may be able to solve spectrum issues that prevented earlier nat-
ural product antibiotics from being exploited fully (Brown et al.,
2014).
SIGNIFICANCE
Antibiotic resistance continues to evolve and grow. There is
a critical need for new antibiotics of novel mechanisms of
action as well as those not cross-resistant to existing drugs.
Antisense-based screens have been useful in discovering
new chemical matter in natural products. Here, we describe
how the technology was adapted to discover DNA replica-
tion inhibitors. In the process, the mechanism of action of
nargenicin, a previously known natural product antibiotic
with a narrow antibacterial spectrum, was identified. This
is the first identification of a natural product inhibitor of
DnaE. Nargenicin-resistant mutants were found to contain1370 Chemistry & Biology 22, 1362–1373, October 22, 2015 ª2015 Ea SNP in dnaE, and subsequent biochemical and microbio-
logical assays corroborated DnaE as the target. While
DnaE is essential and relatively well conserved in all bacte-
ria, in low-GC Gram-positives where PolC is the main repli-
cative polymerase it appears to play a supporting role.
This work highlights the potential of the replisome for inter-
esting targets for antibacterials, as well as the potential to
identify new mechanisms of action from existing natural
products. With newer understanding of the biology of bacte-
rial permeability and efflux as well as pharmacophores that
contribute to efflux substrate potential, medicinal chemistry
may be able to solve spectrum issues that prevented earlier
natural product antibiotics from being exploited fully.
EXPERIMENTAL PROCEDURES
Microbiological Characterization
MICs and kill curves were calculated according to CLSI methods (Clinical and
Laboratory Standards Institute, 2005). Antisense assays for GyrB and ParC
were performed essentially as described by Young et al. (2006) with xylose
concentrations of 10.5 mM and 18 mM, respectively. Isogenic strain sets
used to determine contribution of entry and efflux to antibacterial activity
and macromolecular labeling (MML) were performed as described previously
(Kodali et al., 2005; Robertson et al., 2007). The SOS assay and UvrA reversal
assay to assess DNA damage were performed as described previously (Wang
et al., 2003; Gonzalez del Val et al., 2003). DNA binding was assessed using a
disk-diffusion DNA intercalation assay. In brief, DNA from salmon testes
(Sigma D-1626) was resuspended in sterile water at 10 mg/ml and sonicated
to obtain a homogeneous solution. Sterile filter disks (0.25 inch) were spotted
with 25 ml of the DNA solution and allowed to air dry completely. Compounds
were tested on disks with and without added DNA to assess whether they
bound to DNA. Actinomycin D (Cosmegen for Injection; Merck) was used as
a positive control. Filamentation induced by compound treatment for 2 hr
was observed in MIC wells using a BD Pathway 435 instrument with 603
magnification. For temperature-sensitive filamentation, the mutant was grown
overnight at the permissive temperature (30C) before splitting the culture and
shifting half to the non-permissive temperature (42C) for 2 hr.
Protein Purification
Plasmids encoding E. coli DnaE (amino acids 1–1,160) and S. aureus DnaE
(amino acids 1–1,065) with 6xHis N-terminal tags were overexpressed in
BL21(DE3) and BL21-AI cells (Invitrogen), respectively. Cells were grown in Lu-
ria-Bertani medium to an optical density of 0.45, pelleted, and resuspended
in minimal medium (Pryor and Leiting, 1997). Inducer (0.4 mM isopropyl b-D-1-
thiogalactopyranoside or 0.2% arabinose) was added and cells were incu-
bated for 21 hr at 18C with shaking at 220 rpm. Cells were harvested, frozen
for 20min at80C, and thawed. Pellets were resuspended in 13 Talon buffer
(50 mM sodium phosphate, 300 mM sodium chloride [pH 7.4]) with 10% glyc-
erol and complete protease inhibitor tablets without EDTA (Roche). Cells were
lysed with two passes through a French press and centrifuged for 45 min at
40,000 rpm (70Ti; Beckman). Supernatant was bound to 5 ml of TALON resin
(Clontech) for 1 hr at room temperature and mixed on a Nutator. TALON resin
was washed with 10 mM imidazole, and DnaE was eluted with 250 mM imid-
azole. Eluate was concentrated and run on a size-exclusion column (SEC200;
GE Healthcare) in 25 mM HEPES, 30 mM NaCl, 1 mM CaCl2, and 5% glycerol
(pH 7.9). Size-exclusion column fractions were pooled based on SDS-PAGE
analysis, then aliquoted, frozen, and stored at 80C.
In Vitro DnaE Single-Enzyme Assay
The DnaE single-enzyme assay was a modified version of the standard Pol III
assay using activated DNA and four deoxynucleotide triphosphates (dNTPs)
(Butler and Wright, 2008). In brief, in 96-well plates enzyme was added to a
mixture containing 30 mM Tris-HCl (pH 7.5), 20% glycerol, 4 mM DTT,
10mMMg acetate, 0.025mMdeoxy-ATP, 0.025mMdeoxyguanosine triphos-
phate, 0.025 mM deoxycytidine triphosphate, 0.011 mM [3H]deoxythymidine
triphosphate (dTTP), and 0.298 mg/ml DNase I treated (activated) calf thymuslsevier Ltd All rights reserved
DNA. Assays were initiated by the addition of 0.8 mg/ml E. coli or 0.05 mg/ml
S. aureus DnaE, incubated for 30 min at 30C, and terminated by the addition
of a 20% trichloroacetic acid and 0.2% sodium pyrophosphate solution.
Precipitated, labeled DNA was collected on glass fiber filters, and the filters
were washed, dried, and analyzed in a Microbeta Trilux scintillation counter
(PerkinElmer). Serial dilutionsof compounds inDMSOwereadded to theplates
before enzyme addition. Final DMSO concentration in the assay was 5%.
Resistance Analysis
Frequency of resistance experiments and selection of resistant mutants were
performed as described by Young (2006). Aliquots of overnight cultures were
plated onto agar plates containing 2 mg/ml nargenicin (43 MIC) to determine
the frequency of resistance. The experiment was performed with three inde-
pendent cultures, using approximately 1 3 108 cfu of each culture plated
onto three selective agar plates. Dilutions of cultures were also plated onto
non-selective medium to determine the bacterial counts. Plates were incu-
bated for 48 hr at 35C. Frequencies were determined as the total number of
resistant colonies that formed on selectivemedium divided by the total number
of colony-forming units plated. SNP analysis of resistant mutants was deter-
mined using NimbleGen’s CGS (http://www.nimblegen.com/products/cgs/).
Cloning and Complementation
The dnaE gene, from both wild-type and nargenicin-resistant S. aureus COL
strains, was amplified using Accuprime HiFi (Invitrogen) and cloned into vector
PCR2.1 TOPO via TA cloning according to the manufacturer’s instructions
(Invitrogen). Sequencing confirmed that no PCR errors were introduced (Seq-
wright). The geneswere subcloned into pTet15, anE. coli/S. aureus shuttle vec-
tor with a tetracycline-regulatable promoter in S. aureus. Plasmids were then
sequentially transformed by electroporation into S. aureus RN4220, and finally
into both sensitive and nargenicin-resistant S. aureus COL. MICs of nargenicin
were measured for the plasmid-bearing COL strains in the presence and
absence of added anhydrotetracycline by following the broth dilution suscep-
tibility protocol of the CLSI (Clinical and Laboratory Standards Institute, 2005).
Analysis of Ligand Binding by AS/MS
A23 solutionof ligand inDMSO,unlessotherwisespecified,wasdiluted inbind-
ing buffer (30 mM Tris-HCl [pH 7.5], 4 mM DTT, 10 mM Mg acetate) with 10%
DMSO, and centrifuged for 10 min at 17,933 3 g at 25C. An equal volume of
the 23 ligand solution was added to a 23 solution of protein and transferred
to a 96-well plate for a final concentration of 3.9 mM S. aureus DnaE full-length
or 3.3 mM E. coli DnaE full-length protein in 30 mM Tris-HCl (pH 7.5), 4 mM
DTT, 10 mM Mg acetate, and 5% DMSO. For samples containing protein with
activated DNA, a 33 solution of ligand in DMSO was diluted in binding buffer
and centrifuged for 10 min at 17,933 3 g at 25C. An equal volume of the 33
ligand solution was added to a 33 solution of protein and a 33 solution of acti-
vated DNA, and transferred to a 96-well plate for a final concentration of 3.9 mM
S. aureus DnaE full-length or 3.3 mM E. coli DnaE full-length protein and
0.5mg/ml activated DNA in 30mMTris-HCl (pH 7.5), 4 mMDTT, 10mMMg ac-
etate, and5%DMSO.All sampleswere incubatedat 25C for30min followedby
centrifugation at 1,2663 g for 30min at 4C. Sampleswere then transferred to a
4C autosampler of an Agilent 1100 Series HPLC apparatus.
AS/MS analysis was performed on an integrated SEC-LC-MS platform.
1.5 ml of each sample was injected into a mobile phase of NaH2PO4 (pH 7.5),
at a 300 ml/min flow rate for fast SEC separation with a polyhydroxyethyl aspar-
tamide column (Poly LC, 2.1 3 50 mm, 5 mm particle size, 60 A˚ pore size; The
Nest Group). UV-Based detection triggered a valve to trap and divert the
excluded protein peak to the C18 analytical RPC (0.5 3 50 mm, 5 mm particle
size, 100 A˚ pore size; Higgens Analytical) at a flow rate of 10 ml/min. Small mol-
ecules were dissociated from the protein with 5% CH3CN/95% H2O in 0.2%
formic acid for 3 min, then separated with a gradient of 50% CH3CN/50%
H2O, 0.2% formic acid to 95% CH3CN/5% H2O, 0.2% formic acid over
4 min. The samples flowed directly into the LCT Premiere electrospray time-
of-flight mass spectrometer (Waters). Data were analyzed withMassLynx (Wa-
ters) with a 300-ppm mass chromatogram window.
In Vivo Efficacy
S. aureus target organ assay and MRSA COL murine thigh model were per-
formed essentially as described by Gill et al. (2007). In brief, the target organChemistry & Biology 22, 1362–1assay utilized an MSSA Smith (MB2865) strain to challenge Balb/c mice intra-
peritoneally in 0.5-ml volume 5% hog gastric mucin. Nargenicin at 50 and
25 mg/kg/dose was administered at 10 min and 6 hr post challenge and deliv-
ered by intravenous, oral, and subcutaneous routes. Twenty-four hours after
treatment,micewere euthanized and the kidneys harvested, weighed, homog-
enized, and plated to determine log cfu/g tissue remaining in the nargenicin-
treated group compared with vehicle controls. In the thigh model, DBA/2
micewere challenged intramuscularly in the right hind thighwith 0.2-ml volume
MRSA COL. Nargenicin was administered orally, subcutaneously, and intra-
peritoneally in 0.5-ml volume at 2, 6, 10, and 24 hr post challenge and then
once daily for the next 4 days. One day after the last treatment, mice were
euthanized and the thighs harvested, homogenized, and plated to determine
cfu of bacteria remaining in the nargenicin-treated group compared with
vehicle controls. Pharmacokinetic measurements were performed in C57/
BL6 mice essentially as described by Bateman et al. (2001). All animal exper-
iments were performed in accordance with Merck and the Association for
Assessment and Accreditation of Laboratory Animal Care guidelines for the
ethical treatment of animals.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2015.08.015.
ACKNOWLEDGMENTS
The authors thank Kara Stillmock for mammalian polymerase assays, John Al-
loco for gyrase assays, NimbleGen for comparative array, EurofinsMedinet for
the MRCNS susceptibility studies, the AISS team, Lawrence Colwell for phar-
macokinetic determinations, Priya Dayananth for assistance with microscopy,
and Lynn Silver and Sheo Singh for encouragement. All authors are current or
past employees of Merck & Co., Inc. as stated in affiliations and may receive a
salary or pension, own stock, and/or hold stock options in the company.
Received: May 4, 2015
Revised: August 10, 2015
Accepted: August 25, 2015
Published: October 8, 2015
REFERENCES
Adam, G.C., Parish, C.A., Wisniewski, D., Meng, J., Liu, M., Calati, K., Stein,
B.D., Athanasopoulos, J., Liberator, P., Roemer, T., et al. (2008). Application
of affinity selection mass spectrometry to determine the structural isomer of
parnafungins responsible for binding polyadenosine polymerase. J. Am.
Chem. Soc. 130, 16704–16710.
Aiello, D., Barnes, M.H., Biswas, E.E., Biswas, S.B., Gu, S., William, J.D.,
Bowlin, T.L., and Moir, D.T. (2009). Discovery, characterization and compari-
son of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative
DNA helicases. Bioorg. Med. Chem. 17, 4466–4476.
Bailey, S., Wing, R.A., and Steitz, T.A. (2006). The Structure of T. aquaticus
DNA polymerase III is distinct from eukaryotic replicative DNA polymerases.
Cell 126, 893–904.
Barnes, M.H., Butler, M.M., George, E., Wright, G.E., and Brown, N.C. (2012).
Antimicrobials targeted to the replication-specific DNA polymerases of gram-
positive bacteria: target potential of DnaE. Infect. Disord. Drug Targets 12,
327–331.
Bateman, K.P., Castonguay, G., Xu, L., Rowland, S., Nicoll-Griffith, D.A., Kelly,
N., and Chan, C.-C. (2001). Reduction of animal usage by serial bleeding of
mice for pharmacokinetic studies: application of robotic sample preparation
and fast liquid chromatography-mass spectrometry. J. Chromatogr. B 754,
245–251.
Bax, B.D., Chan, P.F., Eggleston, D.S., Fosberry, A., Gentry, D.R., Gorrec, F.,
Giordano, I., Hann, M.M., Hennessy, A., Hibbs, M., et al. (2010). Type IIA topo-
isomerase inhibition by a new class of antibacterial agents. Nature 466,
935–940.373, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1371
Brotz-Oesterhelt, H., Knezevic, I., Bartel, S., Lampe, T., Warnecke-Eberz, U.,
Ziegelbauer, K., Habich, D., and Labischinski, H. (2003). Specific and potent
inhibition of NAD+-dependent DNA ligase by pyridochromanones. J. Biol.
Chem. 278, 39435–39442.
Brown, F.G., May-Dracka, T.L., Gagnon, M.M., and Tommasi, R. (2014).
Trends and exceptions of physical properties on antibacterial activity for
gram-positive and gram-negative pathogens. J. Med. Chem. 57, 10144–
10161.
Butler, M.M., andWright, G.E. (2008). Amethod to assay inhibitors of DNA pol-
yermase IIIC activity. Methods Mol. Med. 142, 25–36.
Celmer, W.D., Chmurny, G.N., Moppet, C.E., Ware, R.S., Watts, P.C., and
Whipple, E.B. (1980). Structure of natural antibiotic CP-47,444. J. Am.
Chem. Soc. 102, 4203–4209.
Clinical and Laboratory Standards Institute. (2005). Methods for Dilution
Antibacterial Susceptibility Tests for Bacteria that Grow Aerobically—7th
Edition. Approved Standard M7-a7, vol. 23 (CLSI).
Clinical and Laboratory Standards Institute. (2015). Performance Standards for
Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement
M100-S25 (CLSI).
Entenza, J.M., Vouillamoz, J., Glauser, M.P., and Moreillon, P. (1997).
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment
of experimental endocarditis due to methicillin-susceptible or -resistant
Staphylococcus aureus. Antimicrobial. Agents Chemother. 41, 1662–1667.
Friedman, L., Alder, J.D., and Silverman, J.A. (2006). Genetic changes that
correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.
Antimicrobial. Agents. Chemother. 50, 2137–2145.
Forsyth, R.A., Haselbeck, R.J., Ohlsen, K.L., Yamamoto, R.T., Xu, H., Trawick,
J.D., Wall, D., Wang, L., Brown-Driver, V., Froelich, J.M., et al. (2002). A
genome-wide strategy for the identification of essential genes in
Staphylococcus aureus. Mol. Microbiol. 43, 1387–1400.
Gefter, M.L., Hirota, Y., Kornberg, T., Wechsler, J.A., and Barnoux, C. (1971).
Analysis of DNA polymerases II and III in mutants of Escherichia coli thermo-
sensitive for DNA synthesis. Proc. Natl. Acad. Sci. USA 68, 3150–3153.
Gill, C.J., Abruzzo, G.K., Flattery, A.F., Misura, A.S., Bartizal, K., and Hickey,
E.J. (2007). In vivo efficacy of a novel oxazolidinone compound in two mouse
models of infection. Antimicrobial. Agents. Chemother. 51, 3434–3436.
Gonzalez del Val, A., Platas, G., Arenal, F., Orihuela, J.C., Garcia, M.,
Hernandez, P., Royo, I., De Pedro, N., Silver, L.L., Young, K., et al. (2003).
Novel illudins from Coprinopsis episcopalis (syn. Coprinus episcopalis), and
the distribution of illudin-like compounds among filamentous fungi. Mycol.
Res. 107, 1201–1209.
Hawser, S., Lociuro, S., and Islam, K. (2006). Dihydrofolate reductase inhibi-
tors as antibacterial agents. Biochem. Pharmacol. 71, 941–948.
Hishida, T., Han, Y.-W., Shibata, T., Kubota, T., Ishino, Y., Iwasaki, H., and
Shinagawa, H. (2004). Role of the Escherichia coli RecQ DNA helicase in
SOS signaling and genome stabilization at stalled replication forks. Genes
Dev. 18, 1886–1897.
Huber, J., Donald, R.G.K., Lee, S.H., Wang Jarantow, L., Salvatore, M.J.,
Meng, X., Painter, R.E., Onishi, H.R., Occi, J., Dorso, K., et al. (2009).
Chemical genetic identification of peptidoglycan inhibitors potentiating carba-
penem activity against methicillin-resistant Staphylococcus aureus. Chem.
Biol. 16, 837–848.
Infectious Diseases Society of America. (2010). The 10 x ’20 initiative: pursuing
a global commitment to develop 10 new antibacterial drugs by 2020. Clin.
Infect. Dis. 50, 1081–1083.
Jaffe, A., D’Ari, R., and Norris, V. (1986). SOS-independent coupling between
DNA replication and cell division in Escherichia coli. J. Bacteriol. 165, 66–71.
Kodali, S., Galgoci, A., Young, K., Painter, R.E., Silver, L.L., Herath, K.B.,
Singh, S.B., Cully, D., Barrett, J.F., Schmatz, D., and Wang, J. (2005).
Determination of selectivity and efficacy of fatty acid synthesis inhibitors.
J. Biol. Chem. 280, 1669–1677.
Kreuzer, K.N., and Cozzarelli, N.R. (1979). Escherichia coli mutants thermo-
sensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonu-1372 Chemistry & Biology 22, 1362–1373, October 22, 2015 ª2015 Ecleic acid replication, transcription, and bacteriophage growth. J. Bacteriol.
140, 424–435.
Lamers, M.H., Georgescu, R.E., Lee, S.-G., O’Donnell, M., and Kuriyan, J.
(2006). Crystal structure of the catalytic a subunit of E. coli replicative DNA po-
lymerase III. Cell 126, 881–892.
Ling, L.L., Schneider, T., Peoples, A.J., Spoering, A.L., Engels, I., Conlon, B.P.,
Mueller, A., Schaberle, T.F., Hughes, D.E., Epstein, S., et al. (2015). A new anti-
biotic kills pathogens without detectable resistance. Nature 517, 455–459.
Liu, B., Lin, J., and Steitz, T.A. (2013). Structure of the PolIIIa-tc-DNA complex
suggests an atomic model of the replisome. Structure 21, 658–664.
Magerlein, B.J., andMizsak, S.A. (1982). 9-O-esters of nodusmicin. J. Antibiot.
35, 111–112.
Magerlein, B.J., and Reid, R.J. (1982). Synthesis pf 18-deoxynargenicin A1
(antibiotic 367C) from nargenicin-A1. J. Antibiot. 35, 254–255.
Mann, P.A., Mu¨ller, A., Xiao, L., Pereira, P.M., Yang, C., Lee, S.H., Wang, H.,
Trzeciak, J., Schneeweis, J., Moreira dos Santos, M., et al. (2013). Murgocil
is a highly bioactive staphylococcal-specific inhibitor of the peptidoglycan gly-
cosyltransferase enzyme MurG. ACS Chem. Biol. 8, 2442–2451.
O’Donnell, M., and Studwell, P.S. (1990). Total reconstitution of DNA polymer-
ase III holoenzyme reveals dual accessory protein clamps. J. Biol. Chem. 265,
1179–1187.
Page, M.G.P., and Bush, K. (2014). Discovery and development of new anti-
bacterial agents targeting Gram-negative bacteria in the era of pandrug resis-
tance: is the future promising? Curr. Opin. Pharmacol. 18, 91–97.
Payne, D.J., Gwynn,M.N., Holmes, D.J., and Pompliano, D.L. (2007). Drugs for
bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev.
Drug Discov. 6, 29–40.
Phillips, J.W., Goetz, M.A., Smith, S.K., Zink, D.L., Polishook, J., Onishi, H.R.,
Salowe, S., Wiltsie, J., Alloco, J., Sigmund, J., et al. (2011). Discovery of kibde-
lomycin, A potent new class of bacterial Type II topoisomerase inhibitor
by chemical-genetic profiling in Staphylococcus aureus. Chem. Biol. 18,
955–965.
Projan, S.J., and Shlaes, D.M. (2004). Antibacterial drug discovery: is it all
downhill from here? Clin. Microbiol. Infect. 10, 18–22.
Pryor, K.D., and Leiting, B. (1997). High-level expression of soluble protein in
Escherichia coli using a His6-tag and maltose-binding-protein double-affinity
fusion system. Protein Expr. Purif. 10, 309–319.
Pucci, M.J., and Bush, K. (2013). Investigational antimicrobial agents of 2013.
Clin. Microbiol. Rev. 26, 792–821.
Ricard, M., and Hirota, Y. (1973). Process of cellular division inEscherichia coli:
physiological study on thermosensitive mutants defective in cell division.
J. Bacteriol. 116, 314–322.
Robertson, G.T., Doyle, T.B., Du, Q., Duncan, L., Mdluli, K.E., and Lynch, A.S.
(2007). A novel indole compound that inhibits Pseudomonas aeruginosa
growth by targeting MreB is a substrate for MexAB-OprM. J. Bacteriol. 189,
6870–6881.
Robinson, A., Causer, R.J., and Dixon, N.E. (2012). Architecture and conserva-
tion of the bacterial DNA replication machinery, an underexploited drug target.
Curr. Drug Targets 13, 352–372.
Sanders, G.M., Dallmann, H.G., and McHenry, C.S. (2010). Reconstitution of
the B. subtilis replisome with 13 proteins including two distinct replicases.
Mol. Cell 37, 273–281.
Sievert, D.M., Ricks, P., Edwards, J.R., Schneider, A., Patel, J., Srinivasan, A.,
Kallen, A., Limbago, B., and Fridkin, S. (2013). Antimicrobial-resistant patho-
gens associated with healthcare-associated infections: summary of data re-
ported to the National Healthcare Safety Network at the Centers for Disease
Control and Prevention, 2009–2010. Infect. Control Hosp. Epidemiol. 34, 1–14.
Silver, L.L. (2013). Antibacterial discovery: problems and possibilities. In
Antibiotics, C. Gualerzi, L. Brandi, A. Fabbretti, and C. Pon, eds. (Wiley-VCH
Verlag GmbH & Co. KGaA), pp. 23–52.
Singh, S.B., Young, K., and Miesel, L. (2011). Screening strategies for discov-
ery of antibacterial natural products. Expert Rev. Anti Infect. Ther. 9, 589–613.lsevier Ltd All rights reserved
Singh, S.B., Dayananth, P., Balibar, C., Garlisi, C.G., Lu, J., Kishii, R., Takei, M.,
Fukuda, Y., Ha, S., and Young, K. (2015). Kibdelomycin is a bactericidal broad-
spectrum aerobic antibacterial agent. Antimicrobial. Agents Chemother. 59,
3474–3481.
Snyder, W.C., and Rinehart, K.L., Jr. (1984). Biosynthesis of nargenicin and
nodusmicin. J. Am. Chem. Soc. 106, 787–789.
Srivastava, A., Talaue, M., Liu, S., Degen, D., Ebright, R.Y., Sineva, E.,
Chakraborty, A., Druzhinin, S.Y., Chatterjee, S., Mukhopadhyay, J., et al.
(2011). New target for inhibition of bacterial RNA polymerase: ‘switch region’.
Curr. Opin. Microbiol. 14, 532–543.
United States Department of Health and Human Services and Centers for
Disease Control and Prevention. (2013). Antibiotic resistance threats in the
United States. http://www.cdc.gov/drugresistance/threat-report-2013/index.
html.
Vandewiele, D., Ferna´ndez de Henestrosa, A.R., Timms, A.R., Bridges, B.A.,
and Woodgate, R. (2002). Sequence analysis and phenotypes of five temper-
ature sensitive mutator alleles of dnaE, encoding modified a-catalytic subunits
of Escherichia coli DNA polymerase III holoenzyme. Mutat. Res. 499, 85–95.
Wang, J., Galgoci, A., Kodali, S., Herath, K.B., Jayasuriya, H., Dorso, K.,
Vicente, F., Gozalez, A., Cully, D., Bramhill, D., and Singh, S.B. (2003).
Discovery of a small molecule that inhibits cell division by blocking FtsZ, a
novel therapeutic target of antibiotics. J. Biol. Chem. 278, 44424–44428.
Wang, J., Soisson, S.M., Young, K., Shoop,W., Kodali, S., Galgoci, A., Painter,
R.E., Parthasarathy, G., Tang, Y.S., Cummings, R., et al. (2006). Platensimycin
is a selective FabF inhibitor with potent antibiotic properties. Nature 441,
358–361.Chemistry & Biology 22, 1362–1Wang, J., Kodali, S., Lee, S.H., Galgoci, A., Painter, R.E., Dorso, K., Racine, F.,
Motyl, M., Hernandez, L., Tinney, E., et al. (2007). Discovery of platencin, a dual
FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl. Acad. Sci.
USA 104, 7612–7616.
Wing, R.A., Bailey, S., and Steitz, T.A. (2008). Insights into the replisome from
the structure of a ternary complex of the DNA polymerase III a-subunit. J. Mol.
Biol. 382, 859–869.
Wolfson, J.S., and Hooper, D.C. (1989). Fluoroquinolone antimicrobial agents.
Clin. Microbiol. Rev. 2, 378–424.
Young, K. (2006). In vitro antibacterial resistance selection and quantitation. In
Current Protocols in Pharmacology, S.J. Enna, M. Williams, J.F. Barrett, J.W.
Ferkany, T. Kenakin, and R.D. Porsolt, eds. (John Wiley & Sons, Inc), 13A.6.1–
13A.6.22.
Young, K., Jayasuriya, H., Ondeyka, J.G., Herath, K., Zhang, C., Kodali, S.,
Galgoci, A., Painter, R., Brown-Driver, V., Yamamoto, R., et al. (2006).
Discovery of FabH/FabF inhibitors from natural products. Antimicrobial.
Agents Chemother. 50, 519–526.
Zhi, C., Long, Z., Gambino, J., Xu, W., Brown, N.C., Barnes, M., Butler, M.,
LaMarr, W., and Wright, G.E. (2003). Synthesis of substituted 6-anilinouracils
and their inhibition of DNA polymerase IIIC and gram-positive bacterial growth.
J. Med. Chem. 46, 2731–2739.
Zhao, X.Q., Hu, J.F., and Yu, J. (2006). Comparative analysis of eubacterial
DNA polymerase III alpha subunits. Genomics Proteomics Bioinformatics 4,
203–211.373, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1373
